Rempex Drug Patent Portfolio
Rempex owns 2 orange book drugs protected by 10 US patents Given below is the list of Rempex's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11376237 | Methods of treating bacterial infections | 06 Apr, 2039 | Active |
US11944634 | Tetracycline compositions | 16 Oct, 2032 | Active |
US8680136 | Cyclic boronic acid ester derivatives and therapeutic uses thereof | 29 Aug, 2031 | Active |
US10172874 | Pharmaceutical compositions comprising cyclic boronic acid ester derivatives | 08 Aug, 2031 | Active |
US10183034 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | 08 Aug, 2031 | Active |
US10561675 | Cyclic boronic acid ester derivatives and therapeutic uses thereof | 08 Aug, 2031 | Active |
US11007206 | Cyclic boronic acid ester derivatives and therapeutic uses thereof | 08 Aug, 2031 | Active |
US9694025 | Cyclic boronic acid ester derivatives and therapeutic uses thereof | 08 Aug, 2031 | Active |
US9084802 | Tetracycline compositions | 12 May, 2031 | Active |
US9278105 | Tetracycline compositions | 12 May, 2031 | Active |
Latest Legal Activities on Rempex's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Rempex.
Activity | Date | Patent Number |
---|---|---|
Record Petition Decision of Granted to Make Entity Status large | 18 Jul, 2024 | US11007206 |
Patent eCofC Notification | 11 Jun, 2024 | US11944634 |
Recordation of Patent eCertificate of Correction | 11 Jun, 2024 | US11944634 |
Email Notification
Critical
| 11 Jun, 2024 | US11944634 |
Mail Patent eCofC Notification | 11 Jun, 2024 | US11944634 |
Mail Patent eCofC Notification | 30 Apr, 2024 | US11944634 |
Recordation of Patent eCertificate of Correction | 30 Apr, 2024 | US11944634 |
Email Notification
Critical
| 30 Apr, 2024 | US11944634 |
Patent eCofC Notification | 30 Apr, 2024 | US11944634 |
Post Issue Communication - Certificate of Correction | 09 Apr, 2024 | US11944634 |
Patent eGrant Notification | 02 Apr, 2024 | US11944634 |
Patent Issue Date Used in PTA Calculation
Critical
| 02 Apr, 2024 | US11944634 |
Email Notification
Critical
| 02 Apr, 2024 | US11944634 |
Recordation of Patent eGrant | 02 Apr, 2024 | US11944634 |
Mail Patent eGrant Notification | 02 Apr, 2024 | US11944634 |
Rempex's Drug Patent Litigations
Rempex's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 25, 2016, against patent number US10561675. The petitioner , challenged the validity of this patent, with Rempex Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Rempex's patents.
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
US10561675 | November, 2016 |
Decision
(28 Aug, 2018)
| Rempex Pharmaceuticals, Inc. |
Rempex's Family Patents
Rempex Drug List
Given below is the complete list of Rempex's drugs and the patents protecting them.
1. Minocin
Minocin is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11944634 | Tetracycline compositions |
16 Oct, 2032
(8 years from now)
| Active |
US9084802 | Tetracycline compositions |
12 May, 2031
(6 years from now)
| Active |
US9278105 | Tetracycline compositions |
12 May, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Minocin's drug page
2. Vabomere
Vabomere is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11376237 | Methods of treating bacterial infections |
06 Apr, 2039
(14 years from now)
| Active |
US8680136 | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
29 Aug, 2031
(6 years from now)
| Active |
US10172874 | Pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
08 Aug, 2031
(6 years from now)
| Active |
US10183034 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
08 Aug, 2031
(6 years from now)
| Active |
US10561675 | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
08 Aug, 2031
(6 years from now)
| Active |
US11007206 | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
08 Aug, 2031
(6 years from now)
| Active |
US9694025 | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
08 Aug, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vabomere's drug page